Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2026-01-20 @ 4:23 AM
Study NCT ID:
NCT05355168
Status:
COMPLETED
Last Update Posted:
2024-12-31
First Post:
2022-04-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Sponsor:
Anhui Provincial Hospital
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
2021-ky238
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None